Transgene is designing and developing next-generation immunotherapeutics against cancer

Innovative technologies

Push the boundaries of immunotherapy

Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.

Discover our two therapeutic approaches
Discover our technologies

One patient, one cancer, one vaccine

With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.

  myvac® video   Discover myvac®
 Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024

A new generation of products

These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.

  invir.IO® en image   Discover invir.IO®


A therapeutic vaccine in Phase II

TG4001 targets HPV-induced anogenital cancers.

  More information

–> article Home actus

Three therapeutic approaches

Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease. 

Press releases

See all press releases

Last publications

See all publications

A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.